MUMBAI, India & CINCINNATI–(BUSINESS WIRE)–Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, “Sun Pharma”) and LIB Therapeutics Inc. (“LIB”) today announced: An exclusive licensing agreement granting Sun Pharma rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China. Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lo